GenSight Biologics (SIGHT) investor relations material

Executive summary

• 2025 marked a pivotal year with key regulatory milestones, including early access authorizations in France, Israel, and the USA, and successful financing rounds despite a challenging environment.

• Cash runway is projected to extend through December 2026, supporting ongoing development and preparation for the Phase III RECOVER study.

Financial highlights

• Operating income fell 75.2% to €0.7M from €2.6M year-over-year, mainly due to a lower research tax credit and changes in refund liabilities.

• Net loss narrowed by 14% to €12.0M from €14.0M year-over-year; EPS improved to €(0.08) from €(0.15).

• Research and development expenses dropped 47.9% to €6.4M, reflecting prioritization and reduced spending on technology transfer and study preparation.

• General and administrative expenses decreased 12.5% to €4.7M, with cost control offsetting increased personnel costs.

• Cash and cash equivalents stood at €2.4M at year-end 2025, nearly unchanged from €2.5M in 2024.

Outlook and guidance

• Revenues from early access programs in 2026 are expected to cover operating expenses, excluding costs for the new Phase III trial.

• Additional funding will be required to fully finance the RECOVER Phase III trial, with options including debt, equity, expanded access programs, or partnerships.

• Management expects to secure necessary funds before the end of 2026 to avoid delaying the Phase III study.